Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The latest findings from the international INTERGROWTH-21st Project, that has monitored healthy, urban children from educated families across four continents from early pregnancy to 2 years of age, show that human neurodevelopment is not influenced by the colour of an individual’s skin.

None © Shutterstock

The INTERGROWTH-21st Project, funded by the Bill & Melinda Gates Foundation and led by the University of Oxford’s Nuffield Department of Women’s & Reproductive Health, has already shown that healthy, well-nourished women, free of disease, living in a clean environment and receiving good antenatal care have children with similar skeletal growth patterns inside the womb, at birth and up to the age of 2. This research has produced a unique set of international standards for monitoring growth, which perfectly match the existing WHO Child Growth Standards that are being used in virtually every country in the world.

Now, the international consortium of INTERGROWTH-21st researchers has found that attainment in early childhood of neurodevelopmental milestones (relating to cognition, language ability and motor skills) is, like physical growth, very similar among children across diverse geographical and cultural settings, provided that their health and nutritional status are adequate. The findings are unique because neurodevelopmental markers of early childhood have not been studied in this way before.

Read more (University of Oxford website)

Similar stories

Researchers set out steps to address mental health effects of the pandemic on young people

Researchers have outlined 14 steps that schools, mental health services and policymakers can take to help children and young people whose mental health has been affected by the COVID-19 pandemic.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.

No benefit of convalescent plasma for critically ill COVID-19 patients

A large study of over 2000 COVID-19 patients has found that giving critically ill patients blood plasma from recovered COVID-19 patients did not significantly reduce deaths, or the need for intensive care support such as being put on a ventilator machine.

Increased infectiousness of coronavirus variants explained

Researchers from the Universities of Oxford and Dundee have made a discovery that helps explain why variations in the virus causes COVID-19 to spread so rapidly.

RECOVERY Trial paper wins BMJ’s 2021 UK Research Paper of the Year Award

For the second year in a row, The British Medical Journal have selected a publication co-authored by Oxford University researchers for their prestigious UK Research Paper of the Year Award. This award recognises original UK research that has the potential to contribute significantly to improving health and healthcare.

Researchers awarded Wellcome Innovator Grant to investigate role of brainstem nucleus in human consciousness

Researchers at Oxford University have received a prestigious Wellcome Innovator Grant for investigating the role of the pedunculopontine nucleus (PPN) – a brainstem nucleus – in human consciousness.